英国三十所大学在ClinicalTrials.gov的临床试验报告表现:新追踪工具的评估
该研究评估了2017-2018年获得最多医学研究理事会资助的三十所英国大学在美国临床试验注册库ClinicalTrials.gov上是否符合世界卫生组织临床试验报告最佳实践,并开发了新型自动化追踪工具。
要点
- 英国大学在ClinicalTrials.gov的试验结果报告率极低,仅1.6%的到期试验在完成后一年内报告。
- 多数试验(89.8%)未报告结果,平均报告延迟达981天。
- 缺乏对英国赞助方未报告结果的惩罚措施是报告表现差的原因之一。
核心结论
- 英国大学在ClinicalTrials.gov上的临床试验报告合规性差,绝大多数到期试验未及时报告结果。
研究设计与样本
- 评估性研究,针对2017-2018年获医学研究理事会资助最多的三十所英国大学,开发并应用自动化追踪工具。
主要发现
- 89.8%(n=1468)的试验未报告结果,8.6%(n=140)的试验延迟报告。
- 687项试验存在数据不一致,提示大学未能充分更新ClinicalTrials.gov数据。
- 已报告结果的试验平均报告延迟为981天,中位延迟为728天。
- 仅4项试验违反FDAAA 2007。
临床怎么用
- 建议使用自动化追踪工具监测临床试验报告表现,提高透明度。
- 需关注英国大学在ClinicalTrials.gov上的报告延迟和数据更新问题。
局限性
- 研究仅纳入三十所英国大学,结果可能不适用于其他机构。
- 追踪工具依赖注册库数据,可能受数据质量影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trial transparency forms the foundation of evidence-based medicine, and trial sponsors, especially publicly funded institutions such as universities, have an ethical and scientific responsibility to make the results of clinical trials publicly available in a timely fashion. We assessed whether the thirty UK universities receiving the most Medical Research Council funding in 2017-2018 complied with World Health Organization best practices for clinical trial reporting on the US Clinical Trial Registry ( ClinicalTrials.gov ). Firstly, we developed and evaluated a novel automated tracking tool ( clinical-trials-tracker.com ) for clinical trials registered on ClinicalTrials.gov . This tracker identifies the number of due trials (whose completion lies more than 395 days in the past) that have not reported results on the registry and can now be used for all sponsors. Secondly, we used the tracker to determine the number of due clinical trials sponsored by the selected UK universities in October 2020. Thirdly, using the FDAAA Trials Tracker, we identified trials sponsored by these universities that are not complying with reporting requirements under the Food and Drug Administration Amendments Act 2007. Finally, we quantified the average and median number of days between primary completion date and results posting. In October 2020, the universities included in our study were sponsoring 1634 due trials, only 1.6% (n = 26) of which had reported results within a year of completion. 89.8% (n = 1468) of trials remained unreported, and 8.6% (n = 140) of trials reported results late. We also identified 687 trials that contained inconsistent data, suggesting that UK universities often fail to update their data adequately on ClinicalTrials.gov . The mean reporting delay after primary completion for trials that posted results was 981 days, the median 728 days. Only four trials by UK universities violated the FDAAA 2007. We suggest a number of reasons for the poor reporting performance of UK universities on ClinicalTrials.gov : (i) efforts to improve clinical trial reporting in the UK have to date focused on the European clinical trial registry (EU CTR), (ii) the absence of a tracking tool for timely reporting on ClinicalTrials.gov has limited the visibility of institutions' reporting performance on the US registry and (iii) there is currently a lack of repercussions for UK sponsors who fail to report results on ClinicalTrials.gov which should be addressed in the future.
引用
- Keestra SM, Rodgers F, Lenz D, et al. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry. Trials. 2021. PMID: 34074329. doi:10.1186/s13063-021-05330-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。